aureus MRSA Strains in an In Vitro PharmacokineticPharmacodynamicPKPD Model: J. Werth Bhalodi Loo

87 MONDAY SCIENTIFIC SESSIONS Final Program A-612 Comparison of Vancomycin Dosing in Normal Body Habitus, Overweight, and Obese Pediatric Patients

M. P. Nelson

1,2 , D. E. Heble 2 , D. A. Hunstad 3 ; 1 Southern Illinois Univ. Edwardsville, Edwardsville, IL, 2 St. Louis Children’s Hosp., St. Louis, MO, 3 Washington Univ., St. Louis, MO. A-613 Comparing Outpatient Parenteral Antimicrobial Therapy OPAT for Methicillin-Sensitive Staphylococcus aureus MSSA Infection Using an In Vitro Pharmacodynamic Model IPDM

H. Iacovides, C. Huang, S. Zelenitsky; Univ. of Manitoba, Winnipeg, Canada.

A-614 Predictive Performance of Pharmacokinetic Models of Outpa- tients Receiving Vancomycin Continuous Infusions

T. M. Ng

1 , W. P. Lim 1 , M. Chan 1 , D. C. Lye 1 , V. H. Tam 2 ; 1 Tan Tock Seng Hosp., Singapore, Singapore, 2 Univ. of Houston, Houston, TX. A-615 Vancomycin Dose and Duration of Therapy as Risk Factors for Nephrotoxicity in Adult Patients

J. Brown

1 , V. Stevens 1 , K. Brown 2 , N. Onufrak 1 ; 1 SUNY Buffalo Sch. of Pharmacy and Pharmaceutical Sci., Buffalo, NY, 2 Univ. of Rochester Med. Ctr., Rochester, NY. A-616 Vancomycin Nephrotoxicity With or Without Administration of Intravenous Contrast Media

A. Lee

1 , J. Joo 2 , A. Jeng 2 , P. Chan 1 ; 1 Western Univ. of Hlth. Sci., Pomona, CA, 2 Olive View-UCLA Med. Ctr., Sylmar, CA. A-617 Average 24-Hour Area Under the Vancomycin V Serum Concentration-Time Curve AUC, Degree of Nephrotoxicity NT, and Need for Dialysis

V. Stevens

1 , N. Onufrak 1 , K. Brown 2 , J. Brown 1 ; 1 SUNY Buffalo Sch. of Pharmacy and Pharmaceutical Sci., Buffalo, NY, 2 Univ. of Rochester Med. Ctr., Rochester, NY. A-618 Weight-Based Maintenance Dosing of Vancomycin in Hemodialysis D. Ezdon 1 , M. Brown 1,2 , M. Meshay 1 , A. Brophy 1,3 , R. Hickey 1,4 , S. Aggarwal 1,5 , R. Polisetty 1,6 , B. Cuhaci 5 , J. Mitchell 1 , H. P. Schlecht 1,5 ; 1 Hahnemann Univ. Hosp., Philadelphia, PA, 2 Nanticoke Mem. Hosp., Seaford, DE, 3 Mercy St. Vincent Med. Ctr., Toledo, OH, 4 Hosp. of the Univ. of Pennsylvania, Philadelphia, PA, 5 Drexel Univ. Coll. of Med., Philadelphia, PA, 6 Midwestern Univ., Chicago Coll. of Pharmacy, Downers Grove, IL. A-619 Pharmacokinetics of Vancomycin in Patients Undergoing Continuous Venovenous Hemodialysis G. P. Mascara 1 , R. Simpson 1 , R. L. McGill 1,2 , N. H. Chan-Tompkins 1 ; 1 Allegheny Gen. Hosp., Pittsburgh, PA, 2 Drexel Univ. Coll. of Med., Pittsburgh, PA. A-620 PharmacokineticPharmacodynamic PKPD Evaluation of Oritavancin ORI against Staphylococcus aureus SA Using Data from a Murine-Thigh Infection Model O. O. Okusanya 1 , D. Lehoux 2 , A. Forrest 1 , G. Moeck 2 , C. C. Bulik 1 , P. G. Ambrose 1 , S. M. Bhavnani 1 ; 1 ICPD, Latham, NY, 2 The Med. Company, St. Laurent, Canada. A-621 Effect of Telavancin TEL and Vancomycin VAN Clearance on Staphylococcus aureus Activity in an In Vitro Pharmacokinetic Pharmacodynamic PKPD Model of Varying Renal Function

W. Rose

1 , T. Liebenstein 2 , C. Vandevoorde 1 ; 1 Univ. of Wisconsin, Madison, WI, 2 Univ. of Wisconsin Hosp. and Clinics, Madison, WI. A-622 Comparative Activity of Telavancin TLV Combined with Nafcillin NAF, Imipenem IMP, and Gentamicin GEN against Staphylococcus aureus in an In Vitro Pharmacokinetic Pharmacodynamic PKPD Model

S. N. Leonard

1,2 , M. E. Supple 1 ; 1 Northeastern Univ., Boston, MA, 2 Brigham and Women’s Hosp., Boston, MA. A-623 A Single-Center, Randomized, Placebo- and Positive-Con- trolled, Parallel-Group Study of the Electrocardiographic Effects of Dalbavancin in Healthy Male and Female Subjects

M. Dunne

1 , S. R. Moriarty 1 , C. R. Sprenger 2 ; 1 Durata Therapeutics, Mor- ristown, NJ, 2 Cetero Res., Fargo, ND. ------------------------------------------------------------------------ 083A Poster Session Improving Pharmacodynamics of Beta-Lactams and Beta-Lactamase Inhibitors Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-624 fTMIC Predicts Probability of Microbiological Outcome in the Treatment of Nosocomial Pneumonia by Ceftobiprole

A. E. Muller

1 , N. Punt 2 , J. W. Mouton 1 ; 1 UMC St Radboud, Nijmegen, Netherlands, 2 Medimatics, Maastricht, Netherlands. A-624a Monte Carlo Simulations Based on Phase 1 Studies Predict Target Attainment of Ceftobiprole in Nosocomial Pneumonia Patients: A Validation Study

A. Muller

1 , A. H. Schmitt-Hoffmann 2 , N. Punt 3 , J. W. Mouton; 1 UMC St Radboud, Nijmegen, Netherlands, 2 Basilea Pharmaceutica Intl. Ltd, Basel, CH, Basel, Switzerland, 3 Medimatics, Maastricht, Netherlands. A-625 Efficacy of Ceftaroline Fosamil in the Staphylococcal Murine Pneumonia Model A. A. Bhalodi 1 , J. L. Crandon 1 , D. Biek 2 , D. P. Nicolau 1 ; 1 Ctr. for Anti-In- fect. Res. Dev., Hartford Hosp., Hartford, CT, 2 Cerexa, Inc., Oakland, CA. A-626 An Evaluation of Ceftaroline CPT and Daptomycin DAP or Vancomycin VAN Combination against an Isogenic Methi- cillin-Resistant Staphylococcus aureus MRSA Vancomycin In- termediate

S. aureus VISA Pair in an In Vitro Pharmacokinetic Pharmacodynamic PKPD Model

B. J. Werth

1 , G. Sakoulas 2 , W. E. Rose 3 , M. J. Rybak 1 ; 1 Anti-Infective Res. Lab., Wayne State Univ, Detroit, MI, 2 Univ. of California, La Jolla, CA, 3 Univ. of Wisconsin-Madison, Madison, WI. A-627 Evaluation of Ceftaroline CPT Activity against Heterore- sistant Vancomycin Intermediate Staphylococcus aureus hVISA and VISA Methicillin-Resistant

S. aureus MRSA Strains in an In Vitro PharmacokineticPharmacodynamicPKPD Model:

Exploring the “Seesaw Effect”

B. J. Werth

1 , M. E. Steed 2 , G. W. Kaatz 3,4 , M. J. Rybak 1 ; 1 Anti-infective Res. Lab., Wayne State Univ., Detroit, MI, 2 Univ. Kansas Med. Ctr., Kansas City, KS, 3 Wayne State Univ., Detroit, MI, 4 John D. Dingell VA Med. Ctr, Detroit, MI. 88 SCIENTIFIC SESSIONS September 9-12 | A-628 Assessment of the Antistaphylococcal Effect of Ceftaroline in Long Duration Human Dose Simulations: Impact of MIC K. E. Bowker, A. R. Noel, S. Tomaselli, D. L. Nicholls, A. P. MacGowan; Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom. A-629 Pharmacodynamics of Ceftaroline against Enterobacteriaceae K. E. Bowker, A. R. Noel, S. G. Tomaselli, D. L. Nicholls, A. P. MacGowan; Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom. A-630 Efficacy of Humanized Ceftaroline-FosamilAvibactam Expo- sures against Enterobacteriaceae Exhibiting MICs 1 μgmL A. A. Bhalodi 1 , J. L. Crandon 1 , G. Williams 2 , D. P. Nicolau 1 ; 1 Ctr. for Anti-Infect. Res. Dev., Hartford Hosp., Hartford, CT, 2 Cerexa, Inc., Oakland, CA. A-631 The Pharmacodynamics of Avibactam NXL104 in Combina- tion with Either Ceftaroline or Ceftazidime against Blactamase Producing Enterobacteriaceae

A. R. Noel

1 , S. G. Tomaselli 1 , D. L. Nicholls 1 , K. E. Bowker 1 , G. Williams 2 , A. P. MacGowan 1 ; 1 Bristol Ctr. for Antimicrobial Res., Bristol, United King- dom, 2 Cerexa Inc, Oakland, CA, USA, a wholly-owned subsidiary of Forest Lab. Inc, Oakland, CA. A-632 In Vitro Efficacy of Simulated Human Exposures of Ceftazi- dime-Avibactam against Pseudomonas aeruginosa in a Hollow Fiber Model

V. Schuck, M. A. Tanudra, M. Beaudoin, K. Vishwanathan, W. Nichols; AstraZeneca, Waltham, MA.

A-633 Comparative Efficacy of Human Simulated Exposures of Ceftazidime CAZ and Ceftazidime-Avibactam CAZ-AVI against Clinical Pseudomonas aeruginosa Isolates J. L. Crandon, M. Banevicius, D. P. Nicolau; Ctr. for Anti-Infect. Res. Dev., Hartford Hosp., Hartford, CT. A-634 Population Pharmacokinetic Modeling of Ceftazidime CAZ and Avibactam AVI in Healthy Volunteers and Patients with Complicated Intra-Abdominal Infection cIAI J. Li 1 , W. Knebel 2 , M. Riggs 2 , D. Zhou 1 , W. Nichols 3 , S. Das 4 ; 1 Astra- Zeneca, Wilmington, DE, 2 Metrum Res Gp, Tariffville, CT, 3 AstraZeneca, Waltham, MA, 4 AstraZeneca, Alderley Park, United Kingdom. A-635 Evaluation of Ceftazidime-Avibactam CAZ-AVI Dose Regimens for Phase III Study in Patients with Different Renal Function J. Li 1 , D. Zhou 1 , W. Nichols 2 , S. Das 3 ; 1 AstraZeneca, Wilmington, DE, 2 AstraZeneca, Waltham, MA, 3 AstraZeneca, Alderley Park, United King- dom. A-636 Mathematical Modeling of Ceftazidime for High-Flux Hemo- dialysis Patients

A. Loo

1,2 , M. Neely 3 , E. Anderson 2,4 , C. Ghossein 2,4 , M. Griffith 1,2 , M. Scheetz 1,2 ; 1 Midwestern Univ., Downers Grove, IL, 2 Northwestern Mem. Hosp., Chicago, IL, 3 USC Keck Sch. of Med., Los Angeles, CA, 4 North- western Univ. Feinberg Sch. of Med., Chicago, IL. A-637 Standard Dosage Regimens of Broad-Spectrum Beta-Lactams are Inadequate to Treat Difficult-to-Treat Pathogens in Obese Non-Critically Ill Patients M. C. Hites, F. Wolff, F. S. Taccone, E. Maillart, G. Deprez, J. Araci, R. Surin, F. Cotton, F. Jacobs; Erasme Hosp., Free Univ. of Brussels, Brussels, Belgium. A-638 Antibiotic Dosing in Adult Obese Patients: A Calculator for Betalactams, Aminosides, Glycopeptides and Other Antimicrobial Agents N. Lemaire, N. Gauthier, A. Le Joubioux, N. Van Grunderbeeck, S. Barrailler, B. Frimat; Lens Hosp., Lens, France. A-639 Integrating Pharmacodynamics and MIC Distributions to Assess Changing Activity of Amikacin, Cefepime, Ciprofloxacin, Colistin, Gentamicin, Meropenem and Piperacillin-Tazobactam against Clinical Strains of Pseudomonas aeruginosa in Canadian Hospitals from 2007 to 2011

S. Zelenitsky